当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Abstract：

:The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An update with median follow-up times of 17.1, 8.7 and 5.5 years, respectively, is provided. Conditional overall survival (OS) analysis from a 4-year landmark was applied to account for earlier protocol failure owing to disease aggressiveness and toxicities. Cumulative relative survival was computed in the context of age- and gender-matched US population, and interval-specific relative survival ratios were estimated to determine times to normal survival expectation. Based on Cox model-adjusted statistics, OS, progression-free survival and complete-response duration all improved with the transitions from TT1 to TT2 to TT3; improvement was also evident from time-to-progression estimates, 4-year conditional survival data and cumulative relative survival. Interval-specific relative survival normalized progressively sooner, reaching near-normal levels with TT3 in patients who attained complete response. Thus, a strategy using all myeloma-effective agents up-front seems effective at preventing, in progressively larger patient cohorts over time, the outgrowth of resistant tumor cells that account for ongoing relapses.

journal_name

Leukemia

journal_title

Leukemia

authors

Usmani SZ,Crowley J,Hoering A,Mitchell A,Waheed S,Nair B,AlSayed Y,Vanrhee F,Barlogie B

doi

10.1038/leu.2012.160

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

226-32

issue

1

eissn

0887-6924

issn

1476-5551

pii

leu2012160

journal_volume

27

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and l

    abstract：:Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the role of prophylactic...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Morrison FS,Kopecky KJ,Head DR,Athens JW,Balcerzak SP,Gumbart C,Dabich L,Costanzi JJ,Coltman CA,Saiki JH

    更新日期：1992-07-01 00:00:00

  • Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

    abstract：:c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop li...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.94

    authors： Zhao X,Lwin T,Zhang X,Huang A,Wang J,Marquez VE,Chen-Kiang S,Dalton WS,Sotomayor E,Tao J

    更新日期：2013-12-01 00:00:00

  • Infantile leukemia and soybeans--a hypothesis.

    abstract：:Recent molecular-genetic studies have revealed that in the majority of patients with secondary leukemia induced by topoisomerase II (topo II) inhibitors and also with infantile acute leukemia (IAL), the breakpoints are clustered within scaffold attachment regions (SARs) of 3'-MLL-bcr near exon 9. Genistein, abundant i...

    journal_title：Leukemia

    pub_type： 社论

    doi：10.1038/sj.leu.2401344

    authors： Abe T

    更新日期：1999-03-01 00:00:00

  • Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

    abstract：:It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated i...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2011.46

    authors： Martelli AM,Evangelisti C,Chappell W,Abrams SL,Bäsecke J,Stivala F,Donia M,Fagone P,Nicoletti F,Libra M,Ruvolo V,Ruvolo P,Kempf CR,Steelman LS,McCubrey JA

    更新日期：2011-07-01 00:00:00

  • CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

    abstract：:Upregulation of the immunosuppressive cell surface glycoprotein, CD200, is a common feature of acute myeloid leukemia (AML) and is associated with poor patient outcome. We investigated whether CD200 overexpression on AML cells could specifically compromise patient natural killer (NK) cell anti-tumor responses. We foun...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.1

    authors： Coles SJ,Wang EC,Man S,Hills RK,Burnett AK,Tonks A,Darley RL

    更新日期：2011-05-01 00:00:00

  • Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

    abstract：:Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.265

    authors： Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

    更新日期：2018-03-01 00:00:00

  • Studies of decitabine with allogeneic progenitor cell transplantation.

    abstract：:The aim was to determine the efficacy and safety of decitabine in the settings of relapse post-allogeneic progenitor cell transplantation or as part of the conditioning regimen. Three patients (two AML, one ALL) received single agent decitabine 1000 mg/m2 total dose) for treatment of relapse post-transplant (group 1)....

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Giralt S,Davis M,O'Brien S,van Besien K,Champlin R,de Vos D,Kantarjian H

    更新日期：1997-03-01 00:00:00

  • The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

    abstract：:The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation o...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2015.113

    authors： Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

    更新日期：2015-08-01 00:00:00

  • Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.

    abstract：:The transcription factor CCAAT/enhancer binding protein a (C/EBPalpha) is important in the regulation of granulopoiesis and is disrupted in human acute myeloid leukemia. In the present study, we sought to identify novel C/EBPalpha interacting proteins in vivo through immunoprecipitation using mass spectrometry-based p...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404438

    authors： Zada AA,Pulikkan JA,Bararia D,Geletu M,Trivedi AK,Balkhi MY,Hiddemann WD,Tenen DG,Behre HM,Behre G

    更新日期：2006-12-01 00:00:00

  • Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

    abstract：:Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.leu.2404586

    authors： van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

    更新日期：2007-04-01 00:00:00

  • Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.

    abstract：:Epigenetic deregulation is involved in acute myeloid leukemia (AML) pathogenesis and epigenetic targeting drugs are in clinical trial. Since the first results with histone-deacetylase inhibitors in AML are controversial, novel single and combined treatments need to be explored. It is tempting to combine chromatin-targ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.271

    authors： Chaib H,Nebbioso A,Prebet T,Castellano R,Garbit S,Restouin A,Vey N,Altucci L,Collette Y

    更新日期：2012-04-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract：:Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.93

    authors： Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期：2014-10-01 00:00:00

  • BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

    abstract：:Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.358

    authors： Cheng S,Ma J,Guo A,Lu P,Leonard JP,Coleman M,Liu M,Buggy JJ,Furman RR,Wang YL

    更新日期：2014-03-01 00:00:00

  • Deletion of chromosome 2 is an early event in the development of radiation-induced myeloid leukemia in SJL/J mice.

    abstract：:In this study we have analyzed the chromosomal changes in the preleukemic phase in SJL/J mice treated with radiation and acute myeloid leukemias (AMLs) induced by radiation alone or with additional corticosteroid treatment. SJL/J mice exposed to 300 rad whole body irradiation developed a low incidence of AML (20-25%) ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Trakhtenbrot L,Krauthgamer R,Resnitzky P,Haran-Ghera N

    更新日期：1988-08-01 00:00:00

  • bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.

    abstract：:Using the polymerase chain reaction and Southern blot analysis the expression was detected of a bcr-abl mRNA lacking abl exon a2. This was due to a corresponding unusual localization of the breakpoint in the c-abl gene and was seen in a patient with Philadelphia (Ph) chromosome positive chronic myelogeneous leukemia i...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： van der Plas DC,Soekarman D,van Gent AM,Grosveld G,Hagemeijer A

    更新日期：1991-06-01 00:00:00

  • BCL2 mutations in diffuse large B-cell lymphoma.

    abstract：:BCL2 is deregulated in diffuse large B-cell lymphoma (DLBCL) by the t(14;18) translocation, gene amplification and/or nuclear factor-κB signaling. RNA-seq data have recently shown that BCL2 is the most highly mutated gene in germinal center B-cell (GCB) DLBCL. We have sequenced BCL2 in 298 primary DLBCL biopsies, 131 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.378

    authors： Schuetz JM,Johnson NA,Morin RD,Scott DW,Tan K,Ben-Nierah S,Boyle M,Slack GW,Marra MA,Connors JM,Brooks-Wilson AR,Gascoyne RD

    更新日期：2012-06-01 00:00:00

  • Expression of endothelial cell-associated molecules in AML cells.

    abstract：:Recently, it has been clarified that interaction between hematopoietic cells and endothelial cells is important in normal hematopoiesis and leukemogenesis. In this study, we examined the relationship between AML cells and endothelial cells by analyzing the expression profile of angiogenic factors, angiopoietin-1 (Ang-...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402326

    authors： Watarai M,Miwa H,Shikami M,Sugamura K,Wakabayashi M,Satoh A,Tsuboi K,Imamura A,Mihara H,Katoh Y,Kita K,Nitta M

    更新日期：2002-01-01 00:00:00

  • Suppression of G-CSF-mediated Stat signalling by IL-3.

    abstract：:G-CSF-induced myeloid differentiation of 32Dcl3 murine myeloblast cells is antagonized by concurrent exposure to interleukin-3 (IL-3) or by oncogenic transformation of 32Dcl3 by src- or abl-oncogenes which render the cells IL-3-independent. Recent reports have linked G-CSF-mediated differentiation to the ability of G-...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401253

    authors： Steinman RA,Iro A

    更新日期：1999-01-01 00:00:00

  • Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.

    abstract：:The monitoring of chimerism by PCR has become a routine diagnostic approach in patients after allogeneic bone marrow or peripheral blood stem cell transplantation. Nevertheless, a temporal correlation between molecular and hematologic assessment of engraftment has not been clearly established. To address this issue, a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Dubovsky J,Daxberger H,Fritsch G,Printz D,Peters C,Matthes S,Gadner H,Lion T,Muller-Bérat N

    更新日期：1999-12-01 00:00:00

  • SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.

    abstract：:The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine "storm," which in many cases ends in severe acute respiratory syndrome, fulminant m...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-0887-9

    authors： Ratajczak MZ,Kucia M

    更新日期：2020-07-01 00:00:00

  • Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

    abstract：:Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultane...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404139

    authors： Ross DM,Branford S,Moore S,Hughes TP

    更新日期：2006-04-01 00:00:00

  • Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia.

    abstract：:The number of allogeneic transplants from unrelated donors has grown in the past decade in part because of the expansion of the donor registry size. Patient survival has improved due to the selection of more closely matched donors and the development of effective infection prophylaxis. Relapse-free survival remains li...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401648

    authors： Anasetti C

    更新日期：2000-03-01 00:00:00

  • Detection of low abundance mRNA of myeloid specific genes in cells of acute and chronic lymphoid leukemias by cRNA hybridization.

    abstract：:The hybridization to a complementary RNA (cRNA) probe both in situ and in solution was used to assay tiny amounts of mRNA of the lactoferrin (LF) and myeloperoxidase (MPO) genes in normal bone marrow cells and in acute and chronic lymphoid leukemias. Evidence is reported that this technique is much more sensitive than...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Ferrari S,Ceccherelli G,Tagliafico E,Zucchini P,Manfredini R,Torelli G,Emilia G,Torelli U

    更新日期：1990-10-01 00:00:00

  • The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome).

    abstract：:We previously demonstrated that the EVI-1 gene was transcriptionally activated in the 3q21q26 syndrome and chromosomal breakpoints at 3q26 were clustered within 400 Kb of the EVI-1 gene. Since thrombocytosis is often observed in the 3q21q26 syndrome, we first mapped the thrombopoietin (TPO) gene and then we examined f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Suzukawa K,Satoh H,Taniwaki M,Yokota J,Morishita K

    更新日期：1995-08-01 00:00:00

  • Gene therapy against retroviral diseases.

    abstract：:Eventually, gene therapy may be a valid option for chronic viral infections, including retroviral infections. Human retroviral diseases fit two categories: (1) those that result from a monoclonal outgrowth of a human T-cell leukemia virus type I (HTLV-I)-infected cell, as in the case of adult T cell leukemia (ATL); an...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Essex M,Matsuda Z,Yu X,Lee TH

    更新日期：1995-10-01 00:00:00

  • The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.

    abstract：:Retinoic acid receptor (RA) heterodimer (RAR/RXR) activities have been shown to be repressed by transcriptional co-repressor, SMRT/N-CoR, in the absence of the ligand while upon all-trans retionic acid (ATRA) treatment, SMRT/N-CoR is dissociated from RARalpha leading to gene expression by the recruitment of transcript...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401643

    authors： So CW,Dong S,So CK,Cheng GX,Huang QH,Chen SJ,Chan LC

    更新日期：2000-01-01 00:00:00

  • All-trans-retinoic acid effects the growth, differentiation and apoptosis of normal human myeloid progenitors derived from purified CD34+ bone marrow cells.

    abstract：:We have previously shown that all-trans retinoic acid (ATRA) increases the number of CFU-GM colonies grown from unseparated human bone marrow cells with crude sources of colony stimulating factors. In this study, we further characterized the effect of ATRA on the growth of CFU-GM stimulated by individual cytokines fro...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401772

    authors： Douer D,Ramezani L,Parker J,Levine AM

    更新日期：2000-05-01 00:00:00

  • Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?

    abstract：:C-mpl ligand acts primarily as a lineage-specific hematopoietic growth factor by promoting proliferation of megakaryocyte precursors and their differentiation into megakaryocytes and platelets. In addition to the ability of c-mpl ligand to support megakaryocytic development from CD34+ precursor cells, several lines of...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Hofmann WK,Ottmann OG,Hoelzer D

    更新日期：1999-01-01 00:00:00

  • ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.

    abstract：:Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant m...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0159-0

    authors： Triviai I,Zeschke S,Rentel J,Spanakis M,Scherer T,Gabdoulline R,Panagiota V,Thol F,Heuser M,Stocking C,Kröger N

    更新日期：2019-01-01 00:00:00

  • Pathogenesis and prevention of HTLV-1-associated diseases.

    abstract：:HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Miwa M,Kushida S,Maeda N,Fang J,Kawamura T,Kameyama T,Uchida K

    更新日期：1997-04-01 00:00:00